1.Predictive Factors for Depression in Breast Cancer Survivors.
Young Sook TAE ; Suhye KWON ; Jeong Hwa CHOI ; Aeran LEE
Asian Oncology Nursing 2013;13(3):113-120
PURPOSE: This study was to identify the predictive factors for depression in breast cancer survivors. METHODS: The participants were 180 female survivors who visited outpatient clinics after mastectomy or partial resection for breast cancer and had completed adjuvant treatment such as chemotherapy and/or radiation therapy at a university hospital and a general hospital. Data were collected utilizing the Zung depression scale, the Mishel uncertainty scale, the Fitts & Osgoods body image scale, and the Zimet social support scale. RESULTS: The level of depression in the participants was moderate. There were significant correlations among depression, body image, uncertainty, and social support. There were significant differences in depression by education, economic state, perceived health status, fatigue, and pain. In regression analysis, the most powerful predictor of depression was body image (40%). Overall, body image, fatigue, social support, and uncertainty explained 62% of the variance of depression in the participants. CONCLUSION: Body image, fatigue, social support, and uncertainty were important predictors of depression. These results demonstrate the need for interventions to manage depression in breast cancer survivors.
Ambulatory Care Facilities
;
Body Image
;
Breast Neoplasms*
;
Breast*
;
Depression*
;
Drug Therapy
;
Education
;
Fatigue
;
Female
;
Hospitals, General
;
Humans
;
Mastectomy
;
Survivors*
;
Uncertainty
2.Correlations in the results of virus neutralization test, hemagglutination inhibition test, and enzyme-linked immunosorbent assay to determine infectious bronchitis virus vaccine potency.
Mi Ja PARK ; Seong Joon JOH ; Kang Seuk CHOI ; Aeran KIM ; Min Goo SEO ; Jae Young SONG ; Seon Jong YUN
Korean Journal of Veterinary Research 2016;56(3):189-192
The virus neutralization (VN) test was used to determine potency of the infectious bronchitis (IB) vaccine. The results of VN, hemagglutination inhibition (HI), and enzyme-linked immunosorbent assay (ELISA) were compared with those of the IBV M41. The r² values between VN and HI titers and the ELISA antibody titer were 0.8782 and 0.0336, respectively, indicating a high correlation between VN and HI, but not VN and ELISA. The Cohen's kappa coefficient between the VN titer of 2 log₁₀ and HI titer of 5 log₂ was 0.909. Our results showed that VN could be replaced with HI for testing the potency of IBV M41.
Bronchitis
;
Enzyme-Linked Immunosorbent Assay*
;
Hemagglutination Inhibition Tests*
;
Hemagglutination*
;
Infectious bronchitis virus*
;
Neutralization Tests*
;
Vaccine Potency*
3.Comparison of Four Automated Carcinoembryonic Antigen Immunoassays: ADVIA Centaur XP, ARCHITECT I2000sr, Elecsys E170, and Unicel Dxi800.
Joonhong PARK ; Seungok LEE ; Yeongsic KIM ; Aeran CHOI ; Hyeyoung LEE ; Jihyang LIM ; Yonggoo KIM ; Kyungja HAN ; Eun Jee OH
Annals of Laboratory Medicine 2018;38(4):355-361
BACKGROUND: Carcinoembryonic antigen (CEA) is one of the tumor markers available for evaluating disease progression status after initial therapy and monitoring subsequent treatment modalities in colorectal, gastrointestinal, lung, and breast carcinoma. We evaluated the correlations and differences between widely used, automated CEA immunoassays at four different medical laboratories. METHODS: In total, 393 serum samples with CEA ranging from 3.0 to 1,000 ng/mL were analyzed on ADVIA Centaur XP (Siemens Diagnostics, Tarrytown, NY, USA), ARCHITECT i2000sr (Abbott Diagnostics, Abbott Park, IL, USA), Elecsys E170 (Roche Diagnostics, Indianapolis, IN, USA), and Unicel DxI800 (Beckman Coulter, Fullerton, CA, USA), and the results were compared. Deming regression, Passing-Bablok regression, and Bland-Altman analyses were performed to evaluate the data correlation and % differences among these assays. RESULTS: Deming regression analysis of data from Elecsys E170 and UniCel DxI800 showed good correlation (y=3.1615+0.8970x). According to Bland-Altman plot, no statistically significant bias (−1.78 ng/mL [95% confidence interval: −4.02 to 0.46]) was observed between Elecsys E170 and UniCel DxI800. However, the relative differences of CEA concentrations between assays exceeded the acceptable limit of 30%. Regarding the agreement of positivity with cut-off value 5.0 ng/mL, ARCHITECT i2000sr and Elecsys E170 showed the highest agreement (95.2%), whereas ADVIA Centaur XP and ARCHITECT i2000sr showed the lowest agreement (70.7%). CONCLUSIONS: Agreements between automated CEA immunoassays are variable, and individual CEA concentrations may differ significantly between assays. Standardization of serum CEA concentrations and further harmonization are needed.
Bias (Epidemiology)
;
Biomarkers, Tumor
;
Breast Neoplasms
;
Carcinoembryonic Antigen*
;
Disease Progression
;
Immunoassay*
;
Lung
;
Statistics as Topic
4.Large-Scale in-House Cell-Based Assay for Evaluating the Serostatus in Patients with Neuromyelitis Optica Spectrum Disorder Based on New Diagnostic Criteria.
Yeseul KIM ; Gayoung KIM ; Byung Soo KONG ; Ji Eun LEE ; Yu Mi OH ; Jae Won HYUN ; Su Hyun KIM ; AeRan JOUNG ; Byoung Joon KIM ; Kyungho CHOI ; Ho Jin KIM
Journal of Clinical Neurology 2017;13(2):175-180
BACKGROUND AND PURPOSE: The detection of aquaporin 4-IgG (AQP4-IgG) is now a critical diagnostic criterion for neuromyelitis optica spectrum disorder (NMOSD). To evaluate the serostatus of NMOSD patients based on the 2015 new diagnostic criteria using a new in-house cell-based assay (CBA). METHODS: We generated a stable cell line using internal ribosome entry site-containing bicistronic vectors, which allow the simultaneous expression of two proteins (AQP4 and green fluorescent protein) separately from the same RNA transcript. We performed in-house CBA using serum from 386 patients: 178 NMOSD patients diagnosed according to the new diagnostic criteria without AQP4-IgG, 63 high risk NMOSD patients presenting 1 of the 6 core clinical characteristics of NMOSD but not fulfilling dissemination in space, and 145 patients with other neurological diseases, including 66 with multiple sclerosis. The serostatus of 111 definite and high risk NMOSD patients were also tested using a commercial CBA kit with identical serum to evaluate the correlation between the 2 methods. All assays were performed by two independent and blinded investigators. RESULTS: Our in-house assay yielded a specificity of 100% and sensitivities of 80% (142 of 178) and 76% (48 of 63) when detecting definite- and high risk NMOSD patients, respectively. The comparison with the commercial CBA kit revealed a correlation for 102 of the 111 patients: no correlation was present in 7 patients who were seronegative using the commercial method but seropositive using the in-house method, and in 2 patients who were seropositive using the commercial method but seronegative using the in-house method. CONCLUSIONS: These results demonstrate that our in-house CBA is a highly specific and sensitive method for detecting AQP4-IgG in NMOSD patients.
Aquaporin 4
;
Cell Line
;
Humans
;
Methods
;
Multiple Sclerosis
;
Neuromyelitis Optica*
;
Research Personnel
;
Ribosomes
;
RNA
;
Sensitivity and Specificity
5.Development of a Rapid Automated Fluorescent Lateral Flow Immunoassay to Detect Hepatitis B Surface Antigen (HBsAg), Antibody to HBsAg, and Antibody to Hepatitis C.
Ji Hyeong RYU ; Minsuk KWON ; Joung Dae MOON ; Min Woong HWANG ; Jeong Min LEE ; Ki Hyun PARK ; So Jeong YUN ; Hyun Jin BAE ; Aeran CHOI ; Hyeyoung LEE ; Bongsu JUNG ; Juhee JEONG ; Kyungja HAN ; Yonggoo KIM ; Eun Jee OH
Annals of Laboratory Medicine 2018;38(6):578-584
BACKGROUND: Accurate, rapid, and cost-effective screening tests for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection may be useful in laboratories that cannot afford automated chemiluminescent immunoassays (CLIAs). We evaluated the diagnostic performance of a novel rapid automated fluorescent lateral flow immunoassay (LFIA). METHODS: A fluorescent LFIA using a small bench-top fluorescence reader, Automated Fluorescent Immunoassay System (AFIAS; Boditech Med Inc., Chuncheon, Korea), was developed for qualitative detection of hepatitis B surface antigen (HBsAg), antibody to HBsAg (anti-HBs), and antibody to HCV (anti-HCV) within 20 minutes. We compared the diagnostic performance of AFIAS with that of automated CLIAs—Elecsys (Roche Diagnostics GmbH, Penzberg, Germany) and ARCHITECT (Abbott Laboratories, Abbott Park, IL, USA)—using 20 seroconversion panels and 3,500 clinical serum samples. RESULTS: Evaluation with the seroconversion panels demonstrated that AFIAS had adequate sensitivity for HBsAg and anti-HCV detection. From the clinical samples, AFIAS sensitivity and specificity were 99.8% and 99.3% for the HBsAg test, 100.0% and 100.0% for the anti-HBs test, and 98.8% and 99.1% for the anti-HCV test, respectively. Its agreement rates with the Elecsys HBsAg, anti-HBs, and anti-HCV detection assays were 99.4%, 100.0%, and 99.0%, respectively. AFIAS detected all samples with HBsAg genotypes A-F and H and anti-HCV genotypes 1, 1a, 1b, 2a, 2b, 4, and 6. Cross-reactivity with other infections was not observed. CONCLUSIONS: The AFIAS HBsAg, anti-HBs, and anti-HCV tests demonstrated diagnostic performance equivalent to current automated CLIAs. AFIAS could be used for a large-scale HBV or HCV screening in low-resource laboratories or low-to middle-income areas.
Fluorescence
;
Gangwon-do
;
Genotype
;
Hepacivirus
;
Hepatitis B Surface Antigens*
;
Hepatitis B virus
;
Hepatitis B*
;
Hepatitis C*
;
Hepatitis*
;
Immunoassay*
;
Mass Screening
;
Sensitivity and Specificity
;
Seroconversion